M&A in a Solvency II World - An introduction to the S2AV methodology

Similar documents
Embedded Value of Life Insurance Companies in India. Presented by Philip Jackson FIA, FIAI Consulting Actuary

Embedded Value Report

Agenda. Questions Deloitte & Touche LLP Deloitte Advisory Sp. z o.o. Adjusted Net Asset. Value (ANAV)

Effective Financial Planning for Life Insurance Companies

International Financial Reporting for Insurers: IFRS and U.S. GAAP September 2009 Session 25: Solvency II vs. IFRS

GUIDANCE NOTE 252 ACTUARIAL APPRAISALS OF LIFE INSURANCE BUSINESS

Public reporting in a Solvency II environment

Solvency II: recognition of deferred tax

International Financial Reporting for Insurers. August 19-21, Hong Kong. Session 2: Financial Reporting for Insurance Companies.

Rating Methodology for Domestic Life Insurance Companies

Valuation of Life Insurance Companies in India

1. INTRODUCTION AND PURPOSE

Best Estimate of the Technical Provisions

Solvency Management in Life Insurance The company s perspective

GN5: The Prudential Supervision outside the UK of Long-Term Insurance Business

Disclosure of Market Consistent Embedded Value as at March 31, 2015

INSTITUTE AND FACULTY OF ACTUARIES EXAMINATION

Risk Management Metrics Subgroup. Embedded Value Definition

EEV, MCEV, Solvency, IFRS a chance for actuarial mathematics to get to main-stream of insurance value chain

ACCOUNTING STANDARDS BOARD DECEMBER 2004 FRS 27 27LIFE ASSURANCE STANDARD FINANCIAL REPORTING ACCOUNTING STANDARDS BOARD

The Purchase Price in M&A Deals

CEIOPS-DOC-36/09. (former CP 42) October 2009

CIMA F3 Course Notes. Chapter 11. Company valuations

Embedded Value 2014 Report

Quantitative Impact Study 1 (QIS1) Summary Report for Belgium. 21 March 2006

Institute of Actuaries of India

Main Business Indicators

Introduction to Discounted Cash Flow and Project Appraisal. Charles Ward

Market Consistent Embedded Value Principles October CFO Forum

LIFE INSURANCE RATING METHODOLOGY CREDIT RATING AGENCY OF

Capital Management in a Solvency II World & the Role of Reinsurance

Introduction. Coverage. Principle 1: Embedded Value (EV) is a measure of the consolidated value of shareholders interests in the covered business.

Market Consistent Embedded Value (MCEV)

THE APPLICATION OF FUNDAMENTAL VALUATION PRINCIPLES TO PROPERTY/CASUALTY INSURANCE COMPANIES. Abstract

Insurance Mergers and Acquisitions

A Shortcut to Calculating Return on Required Equity and It s Link to Cost of Capital

Regulations in General Insurance. Solvency II

Principles-based Valuation of Life Insurance Products

Olav Jones, Head of Insurance Risk

The future of (Life) Reinsurance Evolution or Revolution?

GLOSSARY. A contract that provides for periodic payments to an annuitant for a specified period of time, often until the annuitant s death.

Disclosure of European Embedded Value as of March 31, 2015

Fifth Quantitative Impact Study of Solvency II (QIS5)

Solvency II Introduction to Pillar 3. Friday 20 th May 2016

Practice Bulletin No. 2

Fair value of insurance liabilities: unit linked / variable business

Impacts of the Solvency II Standard Formula on health insurance business in Germany

Investment in insurance-linked securities. Valuation and modeling approaches for European insurers under Solvency II

GUIDANCE NOTE DETERMINATION OF LIFE INSURANCE POLICY LIABILITIES

International Glossary of Business Valuation Terms*

Principles and models for the Embedded Value calculation

Valuation for merger and acquisition. March 2015

CEIOPS-DOC-33/09. (former CP 39) October 2009

A Primer on Valuing Common Stock per IRS 409A and the Impact of Topic 820 (Formerly FAS 157)

LIFE INSURANCE CAPITAL FRAMEWORK STANDARD APPROACH

Market-Consistent Embedded Value (MCEV)

Guide to Financial Reporting In Irish Life & Permanent plc European Embedded Value and IFRS

A Basic Introduction to the Methodology Used to Determine a Discount Rate

SWEDBANK FÖRSÄKRING AB European Embedded Value

TABLE OF CONTENTS. Executive Summary 3. Introduction 5. Purposes of the Joint Research Project 6

Which WACC when? A cost of capital puzzle

BEL best estimate liability, deduced from the mean loss as a present value of mean loss,

Paper F9. Financial Management. Fundamentals Pilot Paper Skills module. The Association of Chartered Certified Accountants

Insights. Understanding market value margins in options prices. September Background

Guidelines on the valuation of technical provisions

Standard Life plc. Solvency II and capital insight session

Invitation to Comment November 2005 Policyholder Equity of Friendly Societies and AASB 1038 Life Insurance Contracts

AN INTRODUCTION TO REAL ESTATE INVESTMENT ANALYSIS: A TOOL KIT REFERENCE FOR PRIVATE INVESTORS

Solvency II Standard Model for Health Insurance Business

APS2 The Prudential Supervision of Long-Term Insurance Business. Definitions. Legislation or Authority. Application. General

A Primer on Valuing Common Stock per IRS 409A and the Impact of FAS 157

A Primer for Calculating the Swiss Solvency Test Cost of Capital for a Market Value Margin

ON THE RISK ADJUSTED DISCOUNT RATE FOR DETERMINING LIFE OFFICE APPRAISAL VALUES BY M. SHERRIS B.A., M.B.A., F.I.A., F.I.A.A. 1.

Fundamentals Level Skills Module, Paper F9. Section A. Mean growth in earnings per share = 100 x [(35 7/30 0) 1/3 1] = 5 97% or 6%

Leadership in life insurance. April 2015

INTERNATIONAL ASSOCIATION OF INSURANCE SUPERVISORS

Liquidity premiums and contingent liabilities

THE INSURANCE BUSINESS (SOLVENCY) RULES 2015

SECONDARY GUARANTEES FOR UNIT LINKED LIFE INSURANCE THE NEED, FEATURES AND RESERVING

Market Value Margin: Practical calculations under the Solvency II Cost of Capital approach

Featured article: Evaluating the Cost of Longevity in Variable Annuity Living Benefits

Interpretation of Financial Statements

Transcription:

M&A in a Solvency II World - An introduction to the S2AV methodology Presented by Ed Morgan March 17, 2016 Warsaw

Contents 1. Why Solvency II can be very helpful 2. What we saw in recent projects 3. Issues with a TEV approach 4. S2AV Methodology 5. Practical and other issues 2

Contents 1. Why Solvency II can be very helpful 2. What we saw in recent projects 3. Issues with a TEV approach 4. S2AV Methodology 5. Practical and other issues 3

Why Solvency II can be very helpful in an M&A context Cash-flow models TEV, EEV, MCEV Solvency II Simple balance sheet and P&L Simplified valuation: Gordon model (P = D? ) rdr i 4

Why Solvency II can be very helpful in an M&A context It helps to get a clear vision of the attractiveness of possible acquisitions It is an economic valuation approach which also has the rigour of a statutory capital standard (i.e. is subject to supervisor oversight etc) S2 allows non-life and life to be looked at on a consistent standard something not typically done under existing methodologies It captures a risk based view of a company Capital synergies can be identified (e.g. due to diversification, potential for derisking, offsetting risks etc) Valuation upsides can be identified (e.g. conservatism built into approaches) 5

Contents 1. Why Solvency II can be very helpful 2. What we saw in recent projects 3. Issues with a TEV approach 4. S2AV Methodology 5. Practical and other issues 6

What we saw in Recent Projects (1) Buyers are increasingly focusing on Solvency II numbers because: It is now becoming the official capital standard It drives distributable profit (and in particular buyers have worries about need to recapitalise companies after acquisition and/or knowing what dividend stream they can achieve) They want to know what scope there is to improve the numbers or for them to worsen (e.g. due to investment strategies, over-aggressive assumptions etc) They want to quantify capital synergies from combing the acquisition target with their existing businesses At the same time buyers still don t have a good feel for Solvency II numbers They are outside their comfort zone in assessing SII numbers They do not necessarily understand the significance of some methodological choices (e.g. use of transitional measures, risk margin methodology etc) 7

What we saw in Recent Projects (2) Quality of S2 numbers provided by sellers is often quite poor: Often companies are refusing to release detailed SII spreadsheets and prefer to just show some high level results (probably because of a lack of confidence in the numbers) In terms of visibility. E.g. assumptions and methodology are not stated in detail particularly in respect to own funds/technical provisions In terms of process - e.g. multiple linked spreadsheets, messy processes, lack of good documentation etc Dependency on management actions and decisions makes the numbers much more unstable than SI capital position The selling companies themselves are struggling to bed down the figures. Errors are quite common. Projections of Solvency position in particular are often simplistic (e.g. based on high level drivers which are unrealistic) 8

Contents 1. Why Solvency II can be very helpful 2. What we saw in recent projects 3. Issues with a TEV approach 4. S2AV Methodology 5. Practical and other issues 9

Issues with a TEV approach? 10

Issues with a TEV approach Traditional Embedded Value (TEV) approaches have been widely used for M&A work, but may be less relevant under the S2 framework It is difficult to combine TEV approach with S2 for various reasons Discounting projected statutory (Solvency I) profits has various issues: Distributable surpluses depend on movements in own funds and required capital Own funds already capture expected release of prudential margins which would not emerge until the future on a statutory accounting/solvency I basis Solvency II SCR is meant to be consistent with economic value of liabilities (technical provisions), not prudent Solvency I reserves Basing projected required capital on some ratio of Solvency I minimum solvency margin may result in capital running off too slowly It risks mixing apples (market consistent based view of capital) with pears (real world view of future profits) 11

Issues with a TEV approach (example) Assume: 20 year non-participating life liability with a fixed payment after 20 years and no surrender values, expenses or charges (for simplicity). Initial values: Own funds=15, SCR(life)=5, SCR(mkt)=4, Risk Margin =2.7 Investor required return on capital = 10% Example 1 - Solvency II risk-free rate = Solvency I technical rate = 2%, so that BEL = Solvency I mathematical reserve; Assume required capital under both Solvency I and II = SCR Example 2 technical interest rate = 1% => mathematical reserves > BEL Example 3 assume initial required capital under Solvency I = Solvency II SCR; thereafter assume capital changes pro-rata with movement in mathematical reserves (which might be used as a simplifying approach to convert a TEV to be on a SII basis) 12

Issues with a TEV approach (example (cont d)) PV (distributable surplus) at required rate of return 15 10 5 0 Solvency II Solvency I - example 1 Solvency I - example 2 Solvency I - example 3 The base case (i.e. Solvency II ) shows the actual present value of distributable surplus on a SII basis if a full projection was made Example 1: PV (distributable surplus) on a SI basis is higher than SII, as there is no risk margin Example 2: the PV (distributable surplus) reduces due to slower release of surplus (higher reserves under SI) Example 3: the PV (distributable surplus) reduces further due to slower release of required capital under the approximation used 13

Contents 1. Why Solvency II can be very helpful 2. What we saw in recent projects 3. Issues with a TEV approach 4. S2AV Methodology 5. Practical and other issues 14

What valuation methodology makes sense under SII? Is EV needed or is an assessment of own funds (OF) and its trend enough? MCEV and S2 OFs are conceptually similar, but with some differences. Some aspects of MCEV have never gained widespread support, particularly in the context of transactions However S2 numbers have the significant advantage of being on a standardised basis which is used for regulatory reporting and therefore valuers can use (hopefully) robust and readily available models and results There is less scope for cherry picking methodology and assumptions in SII than in EV (since the former is subject to supervisor oversight and is ruled by a well defined norm although with significant choices available that can influence results materially) 15

Two different views of the same thing Under any accounting basis, we have an equivalence between: NPV (projected profits) CoC ( actuarial view ) and NPV (distributable profits) ( investment bankers view ) Conceptually this is because cost of capital represents the cost of delaying distribution of surplus through a need to hold capital. 16

Two different views (2) This equivalence can be demonstrated, supposing required capital C(t) at time t, investment return on capital = i%, discount rate = d% over n years: NPV (distributable profits) = NPV(profits) + n t=1 C t 1 1+i C t (1+d) t = NPV(profits) + C(0)* 1+i n 1 1 + C t ( 1+d t=1 (1+d) t + 1+i (1+d) t+1 = NPV(profits) + C(0) + (i-d) * n 1 t=0 = NPV(profits) + initial capital - CoC C t (1+d) t+1 17

Solvency II Appraisal Value This equivalence carries through into the Solvency II world We define Solvency II Appraisal Value or S2AV which is: NPV (distributable profits under SII) or Adjusted own funds Own funds are adjusted to get the estimated economic value of the shareholders ownership of own funds, We then allow for investors requirements for return on capital by adjusting the risk margin, We allow for any additional value in excess of the cost of capital which the investor believes can be generated by taking hedgeable risks Finally we allow for the franchise value (goodwill) based on the value generation by the company in one year multiplied by a factor reflecting expected new business growth and uncertainty over future volumes and profitability 18

Cost of Capital Adjustment Solvency II Risk Margin methodology allows for the cost of capital Generally investors will have a different view for the following reasons: They may have a different required return on capital They are likely to assume that some hedgeable risks will be taken and want a return on the capital required for these. However we handle this item with an explicit element in our valuation (see next slide) They are likely to assume a need to hold more than SCR as a level of capital (it is unlikely to be possible to run a company at a 100% solvency ratio) This can obviously be done with varying levels of sophistication. 19

Value from Hedgeable Risks If risks are hedgeable, then logically it can be argued that the shareholder is not obliged to take them(*). Therefore it can be argued that the value calculated assuming that no hedgeable risks are taken is a minimum value. Because if taking additional risks did not increase value then it would not be done. In practice a valuation may be desired of the impact of the actual expected situation with some hedgeable risks and hence higher real world expected investment returns and higher capital requirements. It is convenient to separately identify this component in the valuation. Note that the value in the case of participating business should take account of what part of the additional return will go to participating policyholders and the Loss Absorbing Capacity of Technical Provisions which may reduce the SCR (*) It may be considered that on occasions there are other constraints on investment strategy, like the requirements of participating policyholders. This may lead to this value from hedgeable risks being negative. 20

2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 2034 2035 S2 AV example 1 Example: Non-participating life liabilities with 20 year duration Starting own funds of 50 Non-hedgeable risks only (investments in risk-free assets), with initial SCR (life) = 10 and initial Risk Margin of 5.5. If investor s required cost of capital = 6% (as per risk margin), then: PV of distributable surplus = own funds = 50 40 Projected distributable surplus 30 20 10 0-10 -20 distributable surplus change in OF (at start = OF-SCR) less change in SCR 21

2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 2034 2035 S2 AV example 2 Now assume: Investor s required cost of capital = 10% Investor s required capital = 150% of SCR Then: PV of distributable surplus reduces to 45.3 = OF adjustment to risk margin for higher capital and required CoC 40 Projected distributable surplus 30 20 10 0-10 -20 distributable surplus change in OF (at start = OF-SCR) less change in SCR 22

2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 2034 2035 S2 AV example 3 Now assume: Investments made in BBB corporate bonds, with SCRmkt=36.8 Assets still assumed to earn risk free Then: PV of distributable surplus reduces to 21.4 = OF adjustment to risk margin for higher capital and required CoC 40 Projected distributable surplus 30 20 10 0-10 -20 distributable surplus change in OF (at start = OF-SCR) less change in SCR 23

2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 2034 2035 S2 AV example 4 Now assume: Assets earn 2.63% above risk free (which is exactly the rate to compensate the additional capital). Then: PV of distributable surplus increases to 45.3 = as example 2 => Additional return covers increased capital requirement 40 Projected distributable surplus 30 20 10 0-10 -20 distributable surplus change in OF (at start = OF-SCR) less change in SCR 24

Franchise Value (1) It is possible to calculate the value that a year s new premiums adds to the own funds Strictly speaking this should be to own funds allowing for the same adjustments as made previously A marginal basis should be used where possible (e.g. diversification with inforce) The most appropriate way to make the marginal calculation is by calculating an adjusted Solvency II balance sheet and SCR with and without the business included; 25

Franchise Value (2) A new business multiplier should be applied reflecting the expected growth in new business values, trend in margins and associated risk This could allow for factors like the expected underwriting cycle and the value of any distribution agreements. The way in which contract boundaries come into the SII valuation / adjusted own funds may impact future expected volumes and their certainty It may be appropriate to use a higher pre-issue risk discount rate to reflect the uncertainty over the volumes and profitability of future new business 26

Contents 1. Why Solvency II can be very helpful 2. What we saw in recent projects 3. Issues with a TEV approach 4. S2 AV Methodology 5. Practical and other issues 27

Practical and other issues (1) Allocating capital to understand profitability by line Sensitivity to assumptions (in theory allowed for in the standard formula definition, in practice may not reflect real volatility) The standard formula doesn t allow for all risks (e.g. sovereign debt) Transitional measures Availability of information 28

Practical and other issues (2) Simplicity <>= conservativism (e.g. non-allowance for dynamic policyholder behaviour, modelling of management actions) Impact of tax Other constraints on distribution of surplus Local statutory accounting Asset coverage requirements This may be allowed for by having a target level of solvency which reflects any expected constraint on dividend distribution. Standard formula vs alternatives like internal models and USPs Group solvency 29

Questions? Edward Morgan ed.morgan@milliman.com

Legal disclaimer This presentation is intended solely for educational purposes and presents information of a general nature. It is not intended to guide or determine any specific individual situation and persons should consult qualified professionals before taking specific actions. The information contained in the presentation is of a general nature and should not be construed as advice on an individual situation or company. Neither the author, nor the author's employer has certified the information contained in this presentation or guarantee the accuracy and completeness of such information. The use contained in this presentation is voluntary and should not be relied upon unless an independent review of its accuracy and completeness has been performed. Neither the author not the author's employer owe any duty of care to any attendant of this presentation and each expressly disclaims any responsibility for any judgments or conclusions which may result therefrom. Neither the author, nor the author's employer shall have any responsibility or liability to any person or entity with respect to damages alleged to have been caused directly or indirectly by the content of this presentation. 31